Immune suppression by lysosomotropic amines and cyclosporine on T-cell responses to minor and major histocompatibility antigens

Transplantation

Volumn 64, Issue 7, 1997, Pages 1055-1065

  Schultz, Kirk R ^a   Bader, Sharon ^a   Nelson, David ^a   Wang, Ming D ^b   HayGlass, Kent T ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; ANTIMALARIAL AGENT; CHLOROQUINE; CYCLOSPORIN A; CYTOKINE; GAMMA INTERFERON; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT INTERLEUKIN 2;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GRAFT VERSUS HOST REACTION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; CHLOROQUINE; CONCANAVALIN A; CYCLOSPORINE; DRUG SYNERGISM; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HYDROXYCHLOROQUINE; INTERFERON TYPE II; INTERLEUKIN-2; KINETICS; LYMPHOCYTE ACTIVATION; LYSOSOMES; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MINOR HISTOCOMPATIBILITY ANTIGENS; SPLEEN; T-LYMPHOCYTES;

EID: 0030815665     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199710150-00019     Document Type: Article

References (50)

1. Nayak V, Esdaile JM. The efficacy of antimalarials in systemic lupus erythematosus. Lupus 1996; 5 (suppl 1): S23.
2. Kahan A, Menkes CJ. The use of antimalarials in combination with other disease modifying agents in rheumatoid arthritis: the French experience. Lupus 1996; 5 (suppl 1): S45.
3. Landewe RB, Miltenberg AM, Verdank MJ, et al. Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness. Clin Exp Immunol 1995; 102: 144.
4. Landewe RB, Miltenburg AM, Breedveld FC, Daha MR, Dijkmans BA. Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive T cell clones derived from a patient with rheumatoid arthritis. J Rheumatol 1992; 19: 1353.
5. Sperber K, Quaraishi H, Kalb, TH, Panja A, Stecher V, Mayer L. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of IL-1 and IL-6 by monocytes and T cells. J Rheumatol 1993; 20: 803.
6. Nuchtern JG, Biddison WE, Klausner RD. Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature 1990; 343: 74.
7. Lombard-Platlet S, Bertolino P, Deng H, Gerlier D, Rabourdin-Combe C. Inhibition by chloroquine of the class II histocompatibility complex-restricted presentation of endogenous antigens varies according to the cellular origin of the antigen-presenting cells, the nature of the T-cell epitope, and the responding cell. Immunology 1993; 80: 566.
8. Sant AJ, Miller J. MHC class II antigen processing: biology of invariant chain. Curr Opin Immunol 1994; 6: 57.
9. Vogelsang GB, Hess AD. Graft-versus-host disease: new directions for a persistent problem. Blood 1994; 84: 2061.
10. Dietrich PY, Caignard A, Lim A, et al. In vivo T-cell clonal amplification at time of acute graft-versus-host disease. Blood 1994; 84: 2815.
11. Korngold R, Wettstein PJ. Immunodominance in the graft-versus-host response to minor histocompatibility antigens. J Immunol 1990; 145: 4079.
12. Wettstein PJ, Korngold R. Immunodominance in the T-cell responses to multiple non H-2 histocompatibility antigens. IV. Partial tissue distribution and mapping of immunodominant antigens. J Immunol 1987; 139: 2166.
13. Rötzscke O, Falk K. Naturally-occurring peptide antigens derived from the MHC class-I-restricted processing pathway. Immunol Today 1991; 12: 447.
14. Hamilton BL, Parkman R. Acute and chronic graft-versus-host disease induced by minor histocompatibility antigens in mice. Transplantation 1983; 36: 150.
15. Truitt RL, Atasoylu AA. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 1991; 8: 51.
16. van Els CACM, Bakker A, Zwinderman AH, Zwaan FE, van Rood JJ, Goulmy E. Effector mechanisms in graft-versus-host disease in response to minor histocompatibility antigens. II. Evidence of a possible involvement of proliferative T cells. Transplantation 1990; 50: 67.
17. Bunjes D, Theobald M, Nierle T, Arnold R, Heimpel H. Presence of host-specific interleukin-2 T helper cell precursors correlates closely with active primary and secondary chromic graft-versus-host disease. Bone Marrow Transplant 1995; 15: 727.
18. Deeg HJ, Storb R, Thomas ED, et al. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute non-lymphoblastic leukemia. Blood 1985; 65: 1325.
19. Bierer BE. Biology of cyclosporin A and FK506 [Review]. Prog Clin Biol Res 1994; 390: 203.
20. Hess Ad, Tutschka PJ, Santo GW. Effect of cyclosporin A on lymphocyte responses in vitro. III. CsA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primed lymphocytes to TCGF. J Immunol 1982; 128: 355.
21. Schultz KR, Bader S, Paquet J, Li W. Chloroquine treatment affects T cell priming to minor histocompatibility antigens and graft-versus-host disease. Blood 86: 4344, 1995.
22. Gilman AL, Beams F, Tefft M, Mazumder A. The effect of hydroxychloroquine on alloreactivity and its potential use for graft-versus-host disease. Bone Marrow Transplant 1996; 17(6): 1069.
23. Schultz KR. Nelson D. Bader S. synergy between lysosomotropic amines and cyclosporin A on human T-cell responses to an exogenous protein antigen, tetanus toxoid. Bone Marrow Transplant 1996; 18(3): 625.
24. Gilman AL, Morris C, Mogul M, et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease [Abstract]. Blood 1997; 88: 608a.
25. Keown PA, Stiller CR, Laupacis AL, et al.. The effects and side effects of cyclosporine: relationship to drug pharmacokinetics. Transplant Proc 1983; 15: 659.
26. Dijkmans BAC, Vandenborne BEEM, Landewe RBM, Miltenburg AMM,Verweij CL, Breedveld FC. Chloroquine combined with cyclosporine in rheumatoid arthritis: more than the addition of 2 drugs alone. J Rheumatol 1996; 23 (suppl 44): 61.
27. Yang X, Gieni RS, Mosmann TR, HayGlass KT. Chemically modified antigen preferentially elicits induction of Th1-like cytokine synthesis patterns in vivo. J Exp Med 1993; 178: 349.
28. Gieni RS, Li Y, HayGlass KT. Comparison of 3H-thymidine incorporation with MTT and MTS bioassays for human and murine IL-2 and IL-4 analysis: tetrazolium assays provide markedly enhanced sensitivity. J Immunol Methods 1995; 187: 85
29. Lam GKY. The differential aspects of the linear isobole in the study of combined action of agents. Bull Math Biol 1993; 55: 295.
30. Berenbaum MC. Synergy, additivism, and antagonism in immunosuppression: a critical review. Clin Exp Immunol 1977; 28: 1.
31. Chou T-C. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 1976; 59: 253.
32. Kahan BD, Gibbons S, Tejpal N, Stepkowski SM, Chou T-C. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991; 51: 232.
33. Kahan BD, Chou T, Tejpal N, Wang M, Chee C, Stepkowski S. Synergistic effects of cyclosporin analogs-A, D, G, Imm-125-with rapamycin and/or brequinar. Transplant Proc 1994; 26: 3021.
34. Yoshimura N, Kahan BD, Matsui S, Kita M, Hamashima T, Oka T. Cyclosporine effect on immunoregulatory cells in kidney transplant recipients: suppression of gamma-interferon and interleukin production. Transplant Proc 1988; 20(2) (suppl 2): 69.
35. Demotz S. DR αβ dimers from complexes with invariant chain fail to stimulate alloreactive T cell clones. Eur J Immunol 1993; 23: 2100.
36. Koch N, Moldenhauer G, Hofmann WJ, Moller P. Rapid intracellular pathway gives rise to cell surface expression of the MHC class II-associated invariant chain (CD74). J Immunol 1991; 147: 2643.
37. Hu H, Möller G. Lipopolysaccharide-stimulated events in B cell activation. Scand J Immunol 1994; 40: 221.
38. Kennedy MK, Mohler KM, Shanbeck KD, et al. Induction of B cell costimulatory function by recombinant CD40 ligand. Eur J Immunol 1994; 24: 116.
39. Landewe RB, Miltenburg AM, Breedveld FC, Daha MR, Dijkmans BA. Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive T cell clones derived from a patient with rheumatoid arthritis. J Rheumatol 1992; 19: 1353.
40. Demidem A, Taylor JR, Grammer SF, Steilein JW. Effects of chloroquine on antigen-presenting functions of epithelial cells from normal and psoriatic skin. J Invest. Dermatol 1992; 98: 181.
41. Nagai F, Ushiyama K, Kano I, Nakagawa A, Nakao T, Nakajima A. Inhibition of calmodulin stimulation of phosphodiesterase and Ca2+, Mg2+-ATPase activities and shape change of erythrocyte ghosts by chloroquine. Biochem Pharmacol 1987; 36: 3433.
42. Scheibel LW, Colombani PM, Hess AD, Aikawa M, Atkinson CT, Milhous WK. Calcium and calmodulin antagonists inhibit human malaria parasites (Plasmodium falciparum): implications for drug design. Proc Natl Acad Sci USA 1987; 84: 7310.
43. Colombani PM, Bright EC, Monastyrskyj O, Hess AD. Subcellular action of cyclosporine: interaction between CsA and calmodulin antagonists. Transplant Proc 1987; 19: 1171.
44. Colombani PM, Bright EC, Wells M, Hess AD. Drug-drug interaction between cyclosporine and agents affecting calcium-dependent lymphocyte proliferation. Transplant Proc 1989; 21: 840.
45. Ockenfels HM, Nussbaum G, Schultewolter T, et al. Tyrosine phosphorylation in psoriatic T cells is modulated by drugs that induce or improve psoriasis. Dermatology 1995; 191; 217.
46. Landewe RB, Miltenberg AM, Verdank MJ, et al. Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness. Clin Exp Immunol 1995; 102: 144.
47. Ertel W, Morrison MH, Ayala A, Chaudry IH. Chloroquine attenuates hemorrhagic shock-induced suppression of Kupffer cell antigen presentation and major histocompatibility complex class II antigen presentation through blockade of tumor necrosis factor and prostaglandin release. Blood 1991; 78: 1781.
48. Schaffer L, Dallanegra A, Breittmayer JP, Carrel S, Fehlmann M. Monoclonal antibody internalization and degradation during modulation of the CD3/T-cell receptor complex. Cell Immunol 1988; 116: 52.
49. Fox RI. Mechanism of action of hydroxychloroquine as an anti-rheumatic drug. Semin Arthritis Rheum 1993; 23: 82.
50. Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994; 20: 243.